Eledon Pharmaceuticals (ELDN) Total Liabilities (2013 - 2026)

Eledon Pharmaceuticals' Total Liabilities history runs 14 years deep, the most recent figure standing at $46.2 million for Q1 2026.

• Quarterly Total Liabilities fell 1.11% year-over-year to $46.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $46.2 million (down 1.11% YoY) and the FY2025 annual result came in at $32.2 million, down 45.62% from the prior year.
• Total Liabilities was $46.2 million for Q1 2026 at Eledon Pharmaceuticals, up from $32.2 million in the prior quarter.
• Across five years, Total Liabilities topped out at $129.0 million in Q2 2024 and bottomed at $5.1 million in Q1 2022.
• A 5-year average of $45.0 million and a median of $38.9 million in 2025 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2024 — Total Liabilities soared 1171.57% — and 2025, when it slumped 69.86%.
• Eledon Pharmaceuticals' Total Liabilities stood at $8.6 million in 2022, then jumped by 850.73% to $81.9 million in 2023, then slipped by 27.6% to $59.3 million in 2024, then slumped by 45.62% to $32.2 million in 2025, then soared by 43.37% to $46.2 million in 2026.
• Business Quant data shows ELDN's Total Liabilities at $46.2 million in Q1 2026, $32.2 million in Q4 2025, and $38.8 million in Q3 2025.